Navigation Links
Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions

LONDON and PHILADELPHIA, June 5 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced the addition of Prous Science routes of synthesis (ROS) data to the Newport Horizon Premium and Newport Vision Premium solutions. An ROS focused search allows users to identify active pharmaceutical ingredients (APIs) according to an intermediate or reagent used, number of available routes or by patents referenced in a given route. Provided free of charge to current subscribers of the Premium systems, this new dataset, which provides an exciting compliment to the kilogram demand data released in March, enhances product targeting, business development and competitive intelligence by helping users to understand better the chemistry and manufacture of APIs.

The true or original manufacturing process used for a particular API is usually well protected by patents, making it challenging to devise equivalent, cheaper or more efficient processes without infringing on the originator's intellectual property. The new dataset will help to remedy this by providing extensive information for more than 2,500 APIs, consisting of:

-- Full chemical name

-- CAS number

-- Synthesis route diagram

-- Text commentary (with each step indexed to the diagram)

-- Patent references (linked to the patent page)

-- Intermediate chemicals and CAS numbers

-- Reagent chemicals and CAS numbers

-- Scientific journal references

"Understanding the 'recipe' of how a particular active ingredient is made -- or could be made -- is of vital importance to API manufacturers, generic companies and innovators," said Mike Chace-Ortiz, Senior Director, Product Strategy, Thomson Reuters. "By providing access to this important data, Newport Horizon Premium and Newport Vision Premium now allow our customers to gauge which patents are involved, what raw materials are needed, the cost and complexity of the process and whether specialized equipment or facilities must be bought or constructed."

For further information on Thomson Reuters API Intelligence solutions, visit:

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to

SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The Scientific Business of Thomson Reuters Publishes Pharma Matters - a Series of Reviews Covering Various Aspects of the Pharmaceutical Pipeline
2. Thomson Reuters Honors Temple University Health System for Initiative That Cut Costs $64 Million and Grew Clinical Service Lines
3. New Thomson Reuters Biomarkers Report Shines a Light on Revolutionary New Area of Drug Development
4. Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare
5. Thomson Scientific To Honor Australias Top Researchers With Dedicated Australian Research Day
6. Thomson Healthcare Announces Enhancements to Order Sets Solution
7. Thomson Healthcares Clinical Xpert Navigator Tops KLAS Annual Performance Ranking in Mobile Data Systems for Sixth Consecutive Year
8. Thomson Scientific Introduces a New Quarterly Report Identifying the Movers and Shakers in the U.S. Generics Industry
9. Jobson Medical Information LLC Acquires CenterWatch and New England IRB From Thomson Healthcare
10. Saint Barnabas Health Care System Expands Business Relationship with Thomson Healthcare
11. Protalix BioTherapeutics prGCD Named One of the Five Most Promising Drugs Entering Phase III Trials by Thomson Scientific
Post Your Comments:
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Scientific Sessions in Dallas that it will receive two significant new grants to ... came as PHA marked its 25th anniversary by recognizing patients, medical professionals and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)...  MedSource announced today that it has selected ... of choice.  This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: